Efficacy of Metformin for Benign Thyroid Nodules in Subjects With Insulin Resistance: A Systematic Review and Meta-Analysis
Open Access
- 28 August 2018
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 9, 494
Abstract
Background: To evaluate the effect of metformin therapy on decreasing benign thyroid nodule volume in subjects with insulin resistance (IR). Method: Randomized controlled trials (RCTs) and self-controlled trials for the meta-analysis published, before January 31, 2018 were selected from the PubMed, Cochrane Library, Embase, Web of Science, Chinese Biomedical Literature Database, National Knowledge Infrastructure, WANFANG and VIP Database. Pooled standard mean difference with 95% confidence interval was estimated by fixed- or random-effects model depending on heterogeneity. The risk of bias using the Cochrane Collaboration's tool was used to assess the quality of the RCTs contained. The quality of self-controlled studies was evaluated using the Methodological index for non-randomized studies (MINORS) method. Results: 7 studies (3 RCTs and 4 prospective self-controlled studies) with 240 patients were considered to be appropriate for the meta-analysis. The results of the meta-analysis indicated that the volume of thyroid nodule decreased significantly after metformin therapy (SMD −0.62, 95% CI −0.98 ~ −0.27). 6 studies reported the changes of the level of TSH. TSH levels decreased significantly after metformin therapy (SMD −0.27, 95% CI −0.47 ~ −0.07). The pooled data indicated an increase in FT3 level, and an unchanged FT4 level after metformin therapy (FT3, SMD 0.25, 95% CI 0.05 ~ 0.45; FT4, SMD −0.07, 95% CI −0.27 ~ 0.13). HOMA-IR levels decreased significantly after metformin therapy based on the pooled results of 3 RCTs and 3 prospective self-controlled studies (SMD −1.08, 95% CI −1.69 ~ −0.47). Conclusion: The meta-analysis demonstrated that metformin was safe and useful in shrinking benign thyroid nodules volume, improving thyroid function and IR. A large number of high-quality prospective studies still need to be carried out.Keywords
Funding Information
- National Natural Science Foundation of China (81603585)
This publication has 41 references indexed in Scilit:
- Metformin and Thyroid: An UpdateEuropean Thyroid Journal, 2013
- The Cochrane Collaboration's tool for assessing risk of bias in randomised trialsBMJ, 2011
- Thyroidal effect of metformin treatment in patients with polycystic ovary syndromeClinical Endocrinology, 2011
- Metformin Treatment for Small Benign Thyroid Nodules in Patients with Insulin ResistanceMetabolic Syndrome and Related Disorders, 2011
- The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and ElaborationPLOS Medicine, 2009
- TSH-Lowering Effect of Metformin in Type 2 Diabetic PatientsDiabetes Care, 2009
- A Re-Evaluation of Random-Effects Meta-AnalysisJournal of the Royal Statistical Society Series A: Statistics in Society, 2008
- Introducing the Thyroid Gland as Another Victim of the Insulin Resistance SyndromeThyroid®, 2008
- Vergleich der Wirksamkeit zweier verschieden dosierter Levothyroxin-Iodid-Kombinationen in der Therapie der euthyreoten diffusen StrumaDMW - Deutsche Medizinische Wochenschrift, 2001
- Suppressive Therapy with Levothyroxine for Euthyroid Diffuse and Nodular Goiter.Endocrine Journal, 1999